Bacillus Calmette-Guerin (BCG) vaccine injection. In a clinical trial, 120 healthy term neonates who are to receive BCG vaccine in Shahid Sadoughi Hospital, Yazd, Iran will be randomly distributed into three groups (...) one minute after BCG vaccination. In group II, neonates will receive kangaroo mother care ten minutes

BCG vaccination is the national immunization program in Iran and its lymphadenopathy is relatively (...) BCG vaccination has been recommended. Given the existing differences, we decided to design a study to (...) excision) the treatment of suppurative lymphadenitis caused by BCG vaccination. Inclusion criteria: All

Comparison of efficacy of application viable BCG vaccine paste in the treatment of common wart (...) Bacillus Calmette-Guerine(BCG) in the form of paste as a new and safe immunotherapeutic modality in (...) topical BCG paste (BCG+salicylic acid +glycerin) and patients in control group(40 patients) receive

The aim of this study is the evaluation of effect of BCG vaccination in treatment of patients with (...) interventional group, the patients will take BCG vaccination 0.2 cc intradermal in deltoid muscle in baseline, 4 (...) BCG. Measuring fasting blood sugar, C-peptide, HbA1C will be done.

BCG-induced urinary and systemic symptoms and obtaining the correct protocol for BCG administration is. Design: In this study, 120 patients with bladder tumor and candidate for treatment of intercostal BCG who (...) the same time during the six weeks of BCG treatment, and weekly signs were recorded in the designed

randomly receive docetaxel and BCG or BCG alone. The patients were followed up every 3 months to 1year and

Study aim: Assessing the effect of the BCG vaccine on preventing COVID-19 infection in healthcare (...) randomized controlled trial. Groups are determined by block randomization to receive a BCG vaccine or normal (...) , BCG vaccine injection over the past year, having a positive COVID-19 test result. Intervention groups

week. The second group undergoes 6 intravesical BCG injections at intervals of one week. Then (...) intervals In the intervention group and injection of intravesical BCG 6 times with one-week intervals in the

Study aim: Determining the effect of BCG vaccine on glycemic control in type 1 diabetic patients and mean levels of HbA1C, FBS, Anti-GAD and Anti ICA, CBC, NBT and Total IgA before and after BCG vaccine injection. Determine the average HbA1C level every three months for one year. Design: Clinical

Burn patients have the highest metabolic rate among critically ill or injured patients. In this study, we hypothesized that Propranolol would improve healing process and decrease wound healing time. Methods: This study is a double-blind, randomized clinical trial. A total of 79 burn patients, who referred to this center from Jan 2006 to Jan 2007, met the inclusion criteria (patients with burn size 20% to 50% of the total body surface area (TBSA) who were admitted in our center). They were randomly divided into two groups. Patients with cardiac diseases, endocrine diseases, peripheral vascular disease, history of asthma, systolic blood pressure<90 and heart rate<60 after primary resuscitation, and inhalation injuries were excluded. Intervention group received Propranolol orally with the dose of 1mg/kg/day and maximum dose of 1.98 mg/kg/day given in 6 divided doses. This dose will be adjusted to decrease the resting heart rate by 20 percent from each patient's base-line value. The control group received placebo. Patients in both groups were visited on a daily basis by an experienced burn surgeon to determine whether the wounds had an acceptable healing (epithelialization) or were ready for skin graft. Also surface area of wounds needed to be grafted was recorded. The level of hemoglobin of patients were checked biweekly and if it is lower than 10 g/dl, corrected by blood transfusion. Serum albumin levels were also checked biweekly and corrected by administration of intravenous albumin, if it is lower than 3 g/dl.

BCG therapy will be excluded. We have 80 patients in two groups, first group gives diltiazem and

The purpose of this study is to evaluate the potential positive effects of omega-3 fatty acids on anemia and nutritional status in hemodialysis patients with depression. Inclusion criteria: Age more than 16 years old; Initiation of hemodialysis from 3 months ago (at least); Beck depression score equal to or more than 16; Post-dialysis body mass index between 20 and 30. Exclusion criteria: Active underlying chronic inflammatory diseases; Chronic infection and/or acute infection within last month; Asthma or Chronic obstructive pulmonary disease; Other psychiatric disorders; Hypothyroidism; High risk for bleeding; Ingestion of omega-3 supplements in the past 3 months; Intolerance or allergic reaction to fish oil; Ingestion of medications effective on inflammatory markers within the last six weeks. Fifty hemodialysis patients with Beck depression score of equal to or more than16 will be randomized to receive omega-3 fatty acids (1800 mg per day orally) or placebo for 4 months. Before the initiation of the study and at the end of month 4 of the study, pre-dialysis blood samples (10 milliliters) will be taken from all patients to measure serum hemoglobin, transferring, albumin, pre-albumin concentrations . Body mass index, mid arm circumference and Beck depression score will be evaluated at these times as well. The potential effects of omega-3 fatty acids on these laboratory and clinical parameters will be compared between groups.

: patients with heart failure, bradycardia, having background of radiation to bladder, BCG therapy, systolic

Study of efficacy intralesional injection tuberculin antigen in the treatment of multiple common warts. A randomized, double-blind, placebo-controlled clinical trial. Patients and researchers were blinded. Inclusion criteria: Patients with multiple common warts with past history of BCG vaccination or

Study aim: There is no vaccine, drugs or approved treatment for 2019-nCoV because it is not well known and emerging. In this a prospective, phase II trial study, we intend to evaluate the safety and efficacy of using convalescent plasma for passive immunotherapy in patients with 2019-nCoV infection. Design: This is a prospective, phase II trial study. Study will be done on patients who have severe pneumonia following 2019-nCoV infection and hospitalized in the ICU. Convalescent plasma will be used to treat patients. Settings and conduct: Eligible patients who hospitalized in the ICU of Taleghani hospital will candidate for receiving convalescent plasma. Plasma donors will be evaluated based on inclusion and exclusion criteria. An about of 600-900 ml plasma will be obtained from each donor by apheresis. Eligible patients will receive 2 to 3 times ABO-compatible convalescent plasma in final volume of 250-300 ml with 1-day interval. Participants/Inclusion and exclusion criteria: Inclusion criteria of plasma donor Recovery from 2019-nCoV infection according to clinical and laboratory criteria Negative RT-PCR test Negative results of serum/plasma for HBV, HCV, HTLV, HIV, and Syphilis Exclusion criteria of plasma donor Active respiratory infection symptoms: cough, dyspnea, oxygen requirements Fever during 3 days ago Inclusion criteria of recipient Positive 2019- nCoV infection by RT-PCR Respiratory > 30 beats/min SaO2< 93% PaO2 / FiO2 ≤300 mmHg Exclusion criteria of recipient Co-infection with other respiratory viral infection Intervention groups: convalescent plasma therapy in patients with COVID-2019 Main outcome variables: Size of lesion area by Chest CT scan Recovery of clinical symptoms such as fever and respiratory rate PaO2/FiO2 ratio All outcomes will be evaluated on day of 1, 4, 7,14, and 28 after treatment.